Jennifer Lopez welcomes twin babies & other

Sunday 7 September 2008

CV Therapeutics Initiates Phase 1 Clinical Trial Of CVT-3619, A Novel Potential Treatment For Cardiometabolic Diseases

�CV Therapeutics,
Inc. (Nasdaq: CVTX) proclaimed that the company has enrolled the first
patient in a Phase 1 trial of CVT-3619, a novel oral compound for potential
discourse of cardiometabolic diseases. The U.S. Food and Drug
Administration latterly accepted the Company's investigational new drug
application for CVT-3619, a partial A1 adenosine sensory receptor agonist.

This Phase 1 trial volition assess the safety and pharmacokinetic profile
of CVT-3619 in healthy volunteers. The Phase 1 program volition provide early
data on the compound's potential personal effects on circulating levels of free
butterball acids, which are associated with senior high blood lipide levels, insulin
resistance and other cardiometabolic risk factors.

"Despite current therapies, millions of Americans continue to suffer
from both tenderness disease and diabetes. CVT-3619 is a first in class, potent,
orally useable new chemical entity that targets yet untreatable aspects
of dysfunctional metabolism in these patients," said Louis G. Lange, M.D.,
Ph.D., chairman and chief administrator officer of CV Therapeutics. "CVT-3619
was invented by CV Therapeutics and represents our fourth part clinical programme
to complement our deuce approved products."

CVT-3619 binds to the adenosine A1 receptor on fat cells, called
adipocytes, potentially leading to a reduction in the breakdown in fats,
also known as lipolysis, and a lowering of free fat person acids in preclinical
models. Preclinical studies also have shown that CVT-3619 improves insulin
sensitivity, reduces elevated triglycerides, and may lour very low density
lipoproteins and potentially raise heights density lipoproteins.

"CVT-3619 represents a first-in-class agent that appears to inhibit the
release of free fatso acids from fat cells and has the voltage to forgather a
awful unmet need by potentially treating both dyslipidemia and
diabetes. We look forwards to the clinical growth of this innovative
medication," said Ralph A. DeFronzo, M.D., professor of medicine and foreman
of the diabetes division at the University of Texas Health Science Center
in San Antonio, Texas.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a
biopharmaceutical caller primarily focused on applying molecular
cardiology to the discovery, development and commercialization of novel,
small speck drugs for the intervention of cardiovascular diseases. CV
Therapeutics Ltd. is the company's European subsidiary based in the United
Kingdom.

CV Therapeutics' approved products in the United States include
Ranexa(R) (ranolazine extended-release tablets), indicated for the
treatment of chronic angina in patients who suffer not achieved an decent
response with other antianginal drugs, and Lexiscan(TM) (regadenoson)
injection for use as a pharmacological stress agent in radionuclide
myocardial perfusion imaging in patients unable to undergo adequate
exercise stress. Ranexa is too approved for use in the European Union as
add-on therapy for the symptomatic intervention of patients with stable angina
pectoris who are inadequately controlled or intolerant to first-line
antianginal therapies.

Except for the historical information contained herein, the matters set
forth in this press release, including statements as to inquiry and
growth and commercialisation of products, are innovative
statements inside the substance of the "safe harbour" provisions of the
Private Securities Litigation Reform Act of 1995. These advanced
statements ar subject to risks and uncertainties that may case actual
results to differ materially, including operating losses and fluctuations
in operating results; das Kapital requirements; regulative review and approval
of our products; special protocol assessment accord; the carry and
timing of clinical trials; commercialization of products; market acceptation
of products; product labeling; concentrated client base; reliance on
strategic partnerships and collaborations; uncertainties in dose
development; uncertainties regarding cerebral property and other risks
detailed from time to time in CV Therapeutics' SEC reports, including its
Quarterly Report on Form 10-Q for the quarter ended June 30, 2008. CV
Therapeutics disclaims any intent or obligation to update these
forward-looking statements.

CV Therapeutics, Inc.
http://www.cvt.com

View do drugs information on Ranexa.

More information

Monday 18 August 2008

Scarlett Kisses & Tells

It's safe to say Scarlett Johansson has two leading workforce in her life these days.� The low is her fiance, Ryan Reynolds.� The other is Woody Allen.� The actress has asterisked in the last trey films Allen has made--Match Point, Scoop and now� Vicky, Cristina Barcelona, co-starring Penelope Cruz and Javier Bardem.

In the film, the actress shares a controversial smooch with Cruz--one that Johansson admits was more pleasant than she anticipated.

"Everybody wants to know what it was like," she says in an interview with Parade.com. � "Penelope had less facial hair than a guy so it was certainly more pleasant. It� was punter than cuddling Jonathan Rhys-Meyers in Match Point. Kissing him wasn't that bad, but he did take to stop and shave in the middle of a scene even though he'd shaven that break of the day. The man has truly got some beard on him."

Johansson describes her relationship with Allen as "a young charwoman, great-uncle...Let's say a loretta Young blossoming woman and a sort of droopy, Jewish kind of yenta" and calls him a "standup comedian wHO loves an audience."

"Oy, he's such a diva," she jokes.� "He won't do anything until he gets his muffins in the morning.� It's out of control.� Actually, I worship Woody and I'd do anything on one of his movies."

�Vicky Cristina Barcelona deals with different kinds of love and relationships.� The subject matter is perhaps right up Scarlett's alley.� Earlier this year, she became busy to fiance Ryan Reynolds.

"I'm so fortunate to be in a very firm and well-heeled relationship," she says.� "I'm in a honest place in my life right instantly.� I'm a real big believer in loving yourself before you can give love life to person else.� The healthiest and most inspiring relationships are the ones where you're so comfortable with the other person that you actually learn more about yourself that you could never appreciate before."

�
The actress continues, "I don't suppose there's anything wrong with experimenting with different lifestyles, especially when you're whitney Young, but at any time in your life," she says.� "Sometimes you expect something is passing to go one elbow room and it doesn't turn out, or sometimes the unexpected happens and it's positive. If you're non open to that, I think you can't alive life to the fullest."

�

More info

Friday 8 August 2008

Will Radiohead gatecrash ladies' night at the Mercurys?

A clutch of young female singer-songwriters take emerged at the cutting edge of nominations to bring home the bacon the 2008 Nationwide Mercury Prize, traditionally the most seriously regarded of trophies in the music industry's back-slapping calendar.

In fact, such is the abundance of feminine talent they might wish to rename this year's "Mercurys" as the "New Amys", after the turbulent songstress wHO some of the tabloids are anxious to exchange, or level the "Dustys", after the vocalist wHO appears to have elysian a fresh generation of performers.

But the 2008 prize will sadly non be remembered as the "Duffys", granted that the album Rockferry, the highly acclaimed debut from the 24-year-old Welsh warbler Duffy, right, was a surprising omission from the 12-album shortlist.

Among those world Health Organization made the cut were Adele, the 20-year-old union Londoner, world Health Organization underlined her youth by last year naming her first album 19, and Laura Marling, a sandy haired waif from Reading who is barely 18 but is already a highly realised performer, as she demonstrated to a music diligence crowd at the unveiling of the shortlist yesterday in London's Covent Garden.

Beside them on the range call of nominees was Estelle, 28, the benjamin West London-born doorknocker and singer, and Rachel Unthank, the Northumbrian folk singer world Health Organization also performs with her cello and feet and who at 29 is the veteran of this wave of women artists.

Estelle's album Shine includes the single "American Boy", which featured the rapper Kanye West and reached No 1 in March. Adele's 19 has barely been released in the United States and has won her an appearance on The Late Show with David Letterman.

According to Simon Frith, the chairman of the Mercury judges, the list of nominations just reflected the growing muscle of female artists in terms of album gross revenue. "All this says is that in that location are a lot of women making interesting music. If you look at the charts there ar a draw of women there and they ar crossing genres."

None of this cut much ice with the bookies yesterday, as William Hill promptly installed Radiohead as joint favourites to lift the prize for their seventh album, In Rainbows, a release that shocked the music manufacture last year when it was offered to fans as a digital download at a price of their choosing. Although they have dominated the British music scene for more than a decade, Radiohead have never won the Mercury Prize, despite having been shortlisted three times before for OK Computer (1997), Amnesiac (2001), and Hail to the Thief (2003).

In Rainbows � described by the judges yesterday as "a engrossing new chapter in the remarkable Radiohead story" � was offered at fifty-one alongside Alex Turner's new project, The Last Shadow Puppets, which in April released The Age of the Understatement.

As lead singer of the Arctic Monkeys, Turner won the Mercury in 2006 with Whatever People Say I Am, That's What I'm Not.

The achiever of this year's prize will be announced at a London-based ceremony broadcast live on BBC2 on 9 September.

The nominations

Radiohead

In Rainbows

5-1

The album has been critically well-received as more accessible than their previous work.

The Last Shadow Puppets

The Age of the Understatement

5-1

This collaboration of Alex Turner from Arctic Monkeys and Miles Kane from The Rascals reached No 1 in April. Turner won the award in 2006 and was nominated last year.

Robert Plant & Alison Krauss

Raising Sand

6-1

After the success of last year's Led Zeppelin reunion, Plant will be equally proud of this acclaim for his make for with Krauss, who already has a clutch of Grammy Awards to her name.

Elbow

The Seldom Seen Kid

6-1

The Mercury panel heaped praise on Elbow for having produced an "epic rock record" with their fourth album.

Burial

Untrue

6-1

Though at the forefront of this scene, Burial prefers to keep his real identity strange. "Restless, alarming and beguiling," said the judges.

Laura Marling

Alas I Cannot Swim

8-1

Still 18, Marling's debut was described by the panel as consisting of "beautifully composed and emotionally compelling tales of fear and romance".

Adele

8-1

North London graduate of the BRIT School for playing Arts & Technology is inspired by Etta James and Dusty Springfield.

British Sea Power

Do You Like Rock Music?

8-1

"Joyfully eccentric, noisy and exciting," was the panel's verdict on their third album.

Estelle

Shine

8-1

Estelle butt rap, blab out with mortal and ride a lover's rock rhythm method to boot.

Neon Neon

Stainless Style

10-1

This is a conceptual record album based on the life of the maverick motor mogul John DeLorean.

Rachel Unthank &The Winterset

The Bairns

10-1

Folk nomination featuringthe work of the Unthank sisters, Rachel and Becky, from Northumbria.

Portico Quartet

Knee Deep in the North Sea

10-1

Former busking quartet adopted by Hoxton's fashionable Vortex Jazz Club.

More info

Tuesday 1 July 2008

Were There More Jolie Hoaxes?

Elizabeth Snead, who writes the "Dish Rag" blog for the LATimes.com, said today (Friday) that a person claiming to be Angelina Jolie's personal assistant Holly Goline has been "under investigation" by Jolie's lawyers for a year. On Friday, the Goline impostor phoned major media outlets with news that Jolie had given birth to twins. Although the story was picked up by some major news outlets, a spokesperson for Jolie said that it was untrue. Snead indignantly asks why the press was not forewarned about the impostor earlier. "Why have none of the impostor's fraudulent planted stories been debunked by her legal team? What else have we reported that is the result of Angelina's assistant's evil duplicitous doppleganger?" Snead asks.

See Also